Prostate cancer vaccine(Onyvax Ltd.)(Prostate cancer vaccine(Onyvax Ltd.)) - 在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名

ONY-P、Onyvax-P、Prostate cancer vaccine

+ [2]

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

Onyvax Ltd.

在研机构

Onyvax Ltd.

National Cancer Institute

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床试验

EUCTR2006-001619-31-HU / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2008-03-21

申办/合作机构

Onyvax Ltd.

EUCTR2006-001619-31-EE / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2006-10-16

申办/合作机构

Onyvax Ltd.

EUCTR2006-001619-31-LT / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2006-07-17

申办/合作机构

Onyvax Ltd.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的专利（医药）

登录后查看更多信息

4

项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的文献（医药）

2005-10-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-P, Onyvax.

Review

作者: Doehn, Christian ; Jocham, Dieter ; Böhmer, Torsten

Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.

2003-12-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-105, Onyvax.

Article

作者: Blumenthal, Rosalyn D

Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000.

1978-01-01·Chemical and Pharmaceutical Bulletin4区 · 医学

Purification and characterization of bovine parotid hypocalcemic factor obtained via extraction with glacial acetic acid.

4区 · 医学

Article

作者: Hajimu Yamamoto ; Akira Mizutani ; Ikukatsu Suzuki

MeCO-dried powder (PA), obtained from the supernatant left after separation of the pH 5.4-precipitating fraction from the aqueous extract of bovine parotid gland, was extracted with HOAc.The extract had a hypocalcemic activity in rabbits, but its activity fluctuated.The HOAc extract of the Me₂CO-dried powder (PAI) obtained by incubation of a suspension of the sample PA in saline, had nearly constant activity.From the purification of PAI by DEAE-cellulose chromatog. and gel chromatog. on Sephadex G-100, a hypocalcemic protein (P-MSY) was obtained in a yield of 37 mg from 10 kg of fresh gland.The sample P-MSY was homogeneous in disc electrophoresis and electrofocusing and was effective in a dose of 0.01 mg/kg.It has almost the same activity as purified Parotin.P-MSY had a mol. weight of 66,000, isoelec. point of pH 5.60, and sugar content of 2.53%.These properties and the results of amino acid anal. suggest that P-MSY is a hypocalcemic protein differing from purified Parotin.P-MSY was also different from β-Parotin or calcitonin.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺癌	临床2期	-	National Cancer Institute	-
前列腺癌	临床2期	-	Onyvax Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2005	临床2期	转移性前列腺癌	20	ONY-P1	(艱窪構積膚壓顧範淵鏇) = A statistically significant sustained PSA velocity reduction was seen in 3 patients (23%) 淵糧顧鏇淵網遞餘蓋淵 (遞膚網簾觸蓋醖膚製鹹 )	-	2005-06-01